SBIR Phase I: Novel Particulate Fluidization Systems for Pulmonary Drug Delivery Applications

SBIR 第一阶段：用于肺部药物输送应用的新型颗粒流化系统

• 批准号: 0215073
• 负责人: Deepika Singh
• 金额: $ 10万
• 依托单位: SINMAT, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0215073&HistoricalAwards=false
• 关键词: SBIR; Phase; Novel; Particulate; Fluidization

0215073SinghThis Small Business Innovation Research project proposes to develop novel fluidization systems that are needed for synthesis of nano-encapsulated insulin particles for pulmonary drug delivery applications. By coating the insulin particle with very thin (10-50 nm) layer of biodegradable polymers such as polylactic acid (PLA), the sustained release characteristics of insulin can be significantly altered. The unique method has several advantages over conventional methods including low polymer loading, and impurity-free processing. The nano-encapsulation method involves using laser ablation thin film deposition technique to coat drug particles which are fluidized in the gas phase. This Phase I project will develop batch scale fluidization systems which are capable of fluidizing up to 1 kg of particles at a time.The commercial applications of this project are in the area of pharmaceutical drug delivery.

0215073 Singh这个小企业创新研究项目提出开发新型流化系统，该系统是合成用于肺部药物递送应用的纳米胶囊化胰岛素颗粒所需的。通过用生物可降解聚合物如聚乳酸（PLA）的非常薄（10-50 nm）的层涂覆胰岛素颗粒，可以显著改变胰岛素的持续释放特性。这种独特的方法与传统方法相比具有几个优点，包括低聚合物负载和无杂质加工。纳米封装方法涉及使用激光烧蚀薄膜沉积技术来包覆在气相中流化的药物颗粒。该项目的第一阶段将开发批量规模的流化系统，该系统能够一次流化多达1公斤的颗粒。该项目的商业应用是在制药药物输送领域。